Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance

Bibliographic Details
Title: Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
Authors: Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan, Jacob George
Source: Hepatology Communications, Vol 4, Iss 6, Pp 904-915 (2020)
Publisher Information: Wolters Kluwer Health/LWW, 2020.
Publication Year: 2020
Collection: LCC:Diseases of the digestive system. Gastroenterology
Subject Terms: Diseases of the digestive system. Gastroenterology, RC799-869
More Details: Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets. Real‐world studies are needed to inform the impact of widespread DAA treatment on antiviral resistance in the community. The prevalence and range of posttreatment resistance‐associated substitutions (RASs) was determined in Australian patients with open access to DAAs through a wide range of prescribers. NS3, NS5A, and NS5B regions were amplified by polymerase chain reaction and analyzed by population sequencing. Clinically relevant RASs were identified using online databases (ReCALL and Geno2Pheno[hcv]). Of 572 samples, 60% were from genotype 3 and 27% from genotype 1a. Ninety‐two percent of people failed a DAA regimen containing an NS5A inhibitor, including 10% with a pangenotype regimen. NS5A RASs were detected in 72% of people with genotype 1 and 80% with genotype 3. For genotype 1, there was a range of RASs across the NS5A region, while for genotype 3, the Y93H RAS predominated (72%). The prevalence of NS3 RASs was higher in people exposed to an NS3 inhibitor (35% vs. 3.9%; P
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2471-254X
Relation: https://doaj.org/toc/2471-254X
DOI: 10.1002/hep4.1496
Access URL: https://doaj.org/article/2bc40cd708cb429b96c283e8c3599155
Accession Number: edsdoj.2bc40cd708cb429b96c283e8c3599155
Database: Directory of Open Access Journals
More Details
ISSN:2471254X
DOI:10.1002/hep4.1496
Published in:Hepatology Communications
Language:English